News
- Author:
- Nick Mulcahy
Publish date: September 24, 2020
An advisory group to the National Cancer Institute is reviewing the “feasibility and relevance” of the ongoing TM...
News
- Author:
- Nick Mulcahy
Publish date: September 4, 2020
The largest study of its kind found that, with the exception of breast and ovarian cancers, there is no tie betwe...
News
- Author:
- Nick Mulcahy
Publish date: August 5, 2020
The American Society of Clinical Oncology has warned against intravenous infusion of chemotherapy and monoclonal antibodies in cancer patients’ hom...
News
- Author:
- Nick Mulcahy
Publish date: July 31, 2020
Atezolizumab plus cobimetinib and vemurafenib is now approved for BRAF V600mutation-positive advanced melanoma.
News
- Author:
- Nick Mulcahy
Publish date: July 30, 2020
Less toxicity was observed with proton beam therapy than with conventional radiotherapy.
News
- Author:
- Nick Mulcahy
Publish date: July 28, 2020
The FDA granted accelerated approval to brexucabtagene autoleucel, the first approved chimeric antigen receptor (...
News
- Author:
- Nick Mulcahy
Publish date: July 9, 2020
Regular physical activity may reduce the risk of death from alcohol-related cancers.
News
- Author:
- Nick Mulcahy
Publish date: June 30, 2020
The FDA approved a combination of pertuzumab, trastuzumab, and hyaluronidase – administered subcutaneously – for ...
News
- Author:
- Nick Mulcahy
Publish date: June 4, 2020
The ASCO annual meeting went online this year, to mixed reviews. Doubts and hopes coexist about an in-person meet...
News
- Author:
- Nick Mulcahy
Publish date: May 30, 2020
Omeprazole as an addition to treatment for triple-negative breast cancer boosted the expected rate of tumor disap...
News
- Author:
- Nick Mulcahy
Publish date: May 29, 2020
Avelumab maintenance after first-line chemotherapy is a new standard of care for advanced urothelial cancer, acco...
News
- Author:
- Nick Mulcahy
Publish date: May 21, 2020
Olaparib is approved for patients with metastatic, castration-resistant prostate cancer who have deleterious/susp...
News
- Author:
- Nick Mulcahy
Publish date: May 20, 2020
New data suggest rates of regional- and distant-stage prostate cancer have increased annually in the United State...
News
- Author:
- Nick Mulcahy
Publish date: May 18, 2020
Ripretinib is the first-ever drug specifically approved as a fourth-line treatment for advanced gastrointestinal ...
News
- Author:
- Nick Mulcahy
Publish date: May 18, 2020
Nivolumab plus ipilimumab is approved as first-line treatment for patients with metastatic, PD-L1-positive, ALK/E...
